Riassunto
L’acronimo LADA (latent autoimmune diabetes in adults) è stato introdotto nei primi anni’ 90 con l’intento di riconoscere come un’entità patologica a sé stante una forma di diabete autoimmune a insorgenza in età adulta e a lenta progressione che non necessita di trattamento insulinico alla diagnosi. Da allora il LADA è oggetto di innumerevoli controversie che riguardano i diversi aspetti della malattia: dalla sua definizione all’eziopatogenesi, dai criteri diagnostici ai diversi approcci terapeutici. Sebbene ad oggi non sia ancora chiaro quale sia l’atteggiamento terapeutico più appropriato per questa forma di diabete, è certo che un intervento terapeutico ideale dovrebbe non solo favorire un precoce e duraturo mantenimento del compenso glicemico ma agire con azione protettiva sul patrimonio β-cellulare residuo, al fine di evitare o ridurre la progressione delle complicanze croniche del diabete. Considerando che frequentemente la diagnosi di LADA resta misconosciuta e che di fatto pazienti affetti da LADA vengono per lungo tempo considerati come soggetti con diabete di tipo 2, sono necessari studi di intervento che abbiano come obiettivo quello di valutare quale sia il trattamento farmacologico più efficace.
Bibliografia
Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48: 2206, 2005.
Leslie RD, Williams R, Pozzilli P. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 91: 1654, 2006.
Rolandsson O, Palmer JP. Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes! Diabetologia 53: 1250, 2010.
Tiberti C, Giordano C, Locatelli M, Bosi E, Bottazzo GF, Buzzetti R. Identification of tyrosine posphatase 2(256–760) construct as a new, highly sensitive marker for detection of islet autoimmunity in type 2 diabetic patients (The NIRAD Study). Diabetes 57: 1276, 2008.
Brophy S, Yderstraede K, Mauricio D, Hunter S, Hawa M, Pozzilli P, Schernthaner, Schoot N, Buzzetti R, Davies H, Leslie D, Williams R. Action LADA Group. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 31: 439, 2008.
Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML, Bazzigaluppi E, Dotta F, Bosi E. Non Insulin Requiring Autoimmune Diabetes Study Group. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 30: 932, 2007.
Hawa MI, Thivolet C, Mauricio D, Alemanno I, Cipponeri E, Collier D, Hunter S, Buzzetti R, de Leiva A, Pozzilli P, Leslie RD; Action LADA Group. Metabolic syndrome and autoimmune diabetes: Action LADA 3. Diabetes Care 32(1): 160, 2009.
Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function report of an ADA workshop, 21–22 October 2001. Diabetes 53: 250, 2004.
Maruyama T, Tanaka S, Shimada A, Funae O, Kasuga A, Kanatsuka A, Takei I, Yamada S, Harii N, Shimura H, Kobayashi T. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 93: 2115, 2008.
Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346: 1685, 2002.
Rosário PW, Reis JS, Fagundes TA, et al. Latent Autoimmune Di abetes in Adults (LADA): Usefulness of anti-GAD antibody titers and benefit of early insulinization. Arq Bras Endocrinol Metabol 51: 52, 2007.
Yang Z, Zhou Z, Li X, Huang G, Lin J. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract 83: 54, 2009.
Bosi E. Time for testing incretin therapies in early type 1 diabetes? J Clin Endocrinol Metab 95: 2607, 2010.
Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (Dia-Pep277): a randomised, doubleblind, phase II trial. Lancet 358: 1749, 2001.
Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, Cohen IR, Elias D. Treatment of new-onset type 1 diabetes peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabete Metab Res Rev 23: 292, 2007.
Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M, Harris RA, Robertson JA, Lernmark A. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19: 238, 2005.
Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692, 2002.
Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2598, 2005.
Bizzarri C, Pitocco D, Napoli N, Di Stasio E, Maggi D, Manfrini S, Suraci C, Cavallo MG, Cappa M, Ghirlanda G, Pozzilli P; IMDIAB Group. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care 33: 1962, 2010.
Li X, Liao L, Yan X, Huang G, Lin J, Lei M, Wang X, Zhou Z. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 25: 411, 2009.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pozzilli, P., Maurizi, A.R. Quale terapia precoce per il diabete autoimmune dell’adulto?. L’Endocrinologo 12, 2–7 (2011). https://doi.org/10.1007/BF03344774
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03344774